Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Servicio Andaluz De Salud maintains 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners, ensuring that the portfolio's progress is not reliant on a specific individual's review. Furthermore, the workload spans distinct art units, indicating a range of pharmaceutical or biotechnological subject matter currently under examination. This distribution allows the company to gather diverse feedback from various sections of the USPTO.
The busiest examiner, TATGE, LEXUS MARC, is responsible for 1 pending office action. This count shows that the 1 pending office action is part of a workload split among the distinct examiners involved. For practitioners, this distribution suggests a balanced prosecution environment where no examiner or art unit dominates the company's current legal landscape. The strategy should involve monitoring the examiners to identify any diverging requirements that could affect the overall pharmaceutical portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TATGE, LEXUS MARC | 1 | 25.0% | +100.0% |
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704750 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENT | TATGE, LEXUS MARC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611460 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENTS | MARVICH, MARIA | 84d overdue |
| 18704750 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENT | TATGE, LEXUS MARC | — |
| 17488545 | VACCINE AGAINST ACINETOBACTER BAUMANNII BASED ON CELLULAR COMPONENTS DEFICIENT IN LIPOPOLYSACCHARIDE | ZEMAN, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1634 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704750 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENT | TATGE, LEXUS MARC | 1637 | §101§103§112DP | Non-Final OA | — | Pending | Apr 25, 2024 |
| 17611460 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENTS | MARVICH, MARIA | 1634 | §112DP | Non-Final OA | 84d overdue | Pending | Nov 15, 2021 |
| 17488545 | VACCINE AGAINST ACINETOBACTER BAUMANNII BASED ON CELLULAR COMPONENTS DEFICIENT IN LIPOPOLYSACCHARIDE | ZEMAN, ROBERT A | 1645 | §103 | Non-Final OA | — | Pending | Sep 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialServicio Andaluz De Salud has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Lexus Marc Tatge has the most, with 1 of Servicio Andaluz De Salud's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
